ReviewViruses2022
Cross-Reactive Immunity among Five Medically Important Mosquito-Borne Flaviviruses Related to Human Diseases.
Review in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Clinical Landscape and Rate of Exposure to Ilheus Virus: Insights from Systematic Review and Meta-Analysis.Viruses · 2022Pooled it
- Research Advances and Future Perspectives of Point-of-Care Detection Technologies and Biosensors for Mosquito-Borne Viruses.Biosensors · 2026Review
- Serological cross-reactivity and identification of an acute Seoul orthohantavirus case in a dengue outbreak from Vietnam.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2026Article
- Rapid virus-free production of recombinant yellow fever virus envelope protein and its in-depth biophysical analysis.Scientific reports · 2025Article
- Factors determining the outcomes of immune imprinting after repeated orthoflavivirus infections.Frontiers in immunology · 2025Review
- Unveiling reverse vaccinology and immunoinformatics toward Saint Louis encephalitis virus: a ray of hope for vaccine development.Frontiers in immunology · 2025Article
- Subgenomic flaviviral RNAs and human proteins:Computational and structural biotechnology journal · 2024Article
- Preparation and Construction of Chimeric Humanized Broadly Reactive Antibody 10H10 to Protein E of Tick-Borne Encephalitis Virus.Bulletin of experimental biology and medicine · 2024Article
- A broad wastewater screening and clinical data surveillance for virus-related diseases in the metropolitan Detroit area in Michigan.Human genomics · 2024Article
- Antibodies from dengue patients with prior exposure to Japanese encephalitis virus are broadly neutralizing against Zika virus.Communications biology · 2024Article
- Detection and persistence of Zika virus in body fluids and associated factors: a prospective cohort study.Scientific reports · 2023Article
- West Nile virus: The current situation in Egypt.Veterinary world · 2023Article
- Trends in ELISA-Based Flavivirus IgG Serosurveys: A Systematic Review.Tropical medicine and infectious disease · 2023Review
- Serological Cross-Reactivity in Zoonotic Flaviviral Infections of Medical Importance.Antibodies (Basel, Switzerland) · 2023Review
- Evidence of Antibodies against the West Nile Virus and the Usutu Virus in Dogs and Horses from the Southeast of France.Transboundary and emerging diseases · 2023Article
- Pattern ofTropical medicine and infectious disease · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Flaviviruses cause a spectrum of potentially severe diseases. Most flaviviruses are transmitted by mosquitoes or ticks and are widely distributed all over the world. Among them, several mosquito-borne flaviviruses are co-epidemic, and the similarity of their antigenicity creates abundant cross-reactive immune responses which complicate their prevention and control. At present, only effective vaccines against yellow fever and Japanese encephalitis have been used clinically, while the optimal vaccines against other flavivirus diseases are still under development. The antibody-dependent enhancement generated by cross-reactive immune responses against different serotypes of dengue virus makes the development of the dengue fever vaccine a bottleneck. It has been proposed that the cross-reactive immunity elicited by prior infection of mosquito-borne flavivirus could also affect the outcome of the subsequent infection of heterologous flavivirus. In this review, we focused on five medically important flaviviruses, and rearranged and recapitulated their cross-reactive immunity in detail from the perspectives of serological experiments in vitro, animal experiments in vivo, and human cohort studies. We look forward to providing references and new insights for the research of flavivirus vaccines and specific prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.